HEC585 trial for slowing lung scarring decline
Part of Lungs & breathing clinical trials.
This Phase 2 study tests whether HEC585 can slow the decline in lung function in people with progressive fibrosing interstitial lung disease (PF-ILD). It may help preserve breathing capacity and breathing tolerance over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and be willing to sign the consent form and follow study visits.
- You do NOT have idiopathic pulmonary fibrosis (IPF), but you do have progressive fibrosing interstitial lung disease confirmed on chest CT.
- Despite at least 3 months of usual care, you must show recent worsening (symptoms, lung function test changes, and/or scan changes) within the past 12 months.
- Your basic lung function tests must meet limits (FEV1/FVC at least 0.7 before bronchodilators, and %FVC at least 45% predicted).
- Your DLCO (a gas-exchange test) must be between 30% and 80% of predicted.
- If you have connective-tissue disease-related lung disease, your treatment must have been stable for 12 weeks before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
This trial tests a new drug called HRS-9813 for people with pulmonary fibrosis (scarring in the lungs) that continues to worsen. It looks at whether the drug can slow down the disease compared to a placebo.
This study tests whether a new drug called HSK44459 can slow lung scarring (idiopathic pulmonary fibrosis or IPF) and improve your ability to breathe. You'll receive either the drug or a placebo while your lung function is monitored over time.
This trial tests a new medicine called HSK44459 for people with progressive pulmonary fibrosis (PPF). It aims to see if the drug can help slow lung damage and improve breathing. You may join if you are not taking certain other fibrosis drugs or have been on a stable dose for at least 12 weeks.
This study tests whether a new tablet called SYH2059 can help slow lung scarring in adults with idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes thick and stiff over time. You'll take the study drug alongside your current lung treatment to see if it improves your breathing and lung function.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
Hear when a new Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.